Aktis to collaborate with Eli Lilly on cancer therapies
The Boston-based drug developer will use its proprietary technology along with Lilly’s expertise in oncology drugs to develop therapies for a range of solid tumors.
If you are not happy with the results below please do another search
The Boston-based drug developer will use its proprietary technology along with Lilly’s expertise in oncology drugs to develop therapies for a range of solid tumors.
Today the company announced that its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
The drug, called depemokimab, showed “significant and meaningful reductions” in asthma attacks for patients with eosinophilic asthma, the company stated.
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.
In recognition of Clinical Trials Day, The Trial for #ClinicalEquality –a longstanding and widely celebrated initiative from FCB Health New York, an IPG Health company – continues the fight to increase equity in clinical trials with the next phase of its campaign entitled, “Worth Less.”
Earlier this month, Neuralink said tiny wires implanted in the brain of its first patient had pulled out of position. Reuters reported last week, citing sources, the company knew from animal testing that the wires might retract.
H4B Chelsea President Violet Aldaia was recently elected the new board chair of the Coalition for Healthcare Communication (CHC). Med Ad News spoke with Aldaia to get a quick take on the issues she feels are most important for CHC to address this year.
Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso.
In an oral decision, the European patent authority maintained the validity of Moderna’s patent ‘949 which describes and protects specific alterations to mRNA molecules designed to lower its immunogenicity, bypass the immune system and boost its translation in the body—as well as the potential uses of the modified mRNA.
According to key opinion leaders (KOLs) interviewed by GlobalData, the prevalence of HIV will reduce in the future, partly due to better treatment options, the availability of PrEP, and the development of prophylactic vaccines.